Capital Fund Management S.A. Invests $793,000 in Omnicell, Inc. $OMCL

Key Points

• Capital Fund Management S.A. has acquired 22,682 shares of Omnicell, Inc., valued at approximately $793,000, amidst increasing institutional interest in the company.
• Omnicell recently reported an EPS of $0.45 for the last quarter, exceeding analysts' expectations, and projects a target EPS range of 1.400-1.650 for FY 2025.
• Analysts have mixed ratings on Omnicell, with a consensus rating of "Moderate Buy" and a target price of $46.71, despite recent fluctuations in stock ratings.

Capital Fund Management S.A. bought a new stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 22,682 shares of the company's stock, valued at approximately $793,000.

Several other institutional investors have also modified their holdings of OMCL. Johnson Financial Group Inc. bought a new stake in Omnicell in the 4th quarter valued at about $37,000. Point72 Hong Kong Ltd acquired a new stake in shares of Omnicell in the fourth quarter valued at approximately $101,000. Corton Capital Inc. bought a new stake in shares of Omnicell during the fourth quarter valued at approximately $208,000. Caption Management LLC acquired a new position in shares of Omnicell during the fourth quarter worth approximately $223,000. Finally, New Age Alpha Advisors LLC acquired a new position in shares of Omnicell during the first quarter worth approximately $233,000. Institutional investors own 97.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Wells Fargo & Company lifted their target price on Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research note on Monday, July 21st. Bank of America raised their price target on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a report on Friday, May 23rd. Piper Sandler reduced their price objective on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, August 11th. Benchmark decreased their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Wall Street Zen cut shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Omnicell has an average rating of "Moderate Buy" and a consensus price target of $46.71.

Omnicell Price Performance

Omnicell stock traded down $0.69 during midday trading on Friday, hitting $32.59. The company's stock had a trading volume of 595,171 shares, compared to its average volume of 577,128. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.74. The company has a quick ratio of 1.24, a current ratio of 1.42 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $1.50 billion, a PE ratio of 65.18, a price-to-earnings-growth ratio of 7.27 and a beta of 0.78. The stock's 50-day moving average price is $30.07 and its 200-day moving average price is $31.62.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The company had revenue of $290.56 million during the quarter, compared to analyst estimates of $275.57 million. During the same quarter last year, the firm posted $0.51 EPS. The business's revenue for the quarter was up 5.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.